Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00035024.xml
Download PDF
Thromb Haemost 2008; 99(01): 235-237
DOI: 10.1160/TH07-06-0396
DOI: 10.1160/TH07-06-0396
Case Report
Concurrent thalidomide and radiation therapy for extensive arterio-venous malformations
Authors
Further Information
Correspondence to:
Ales Blinc, MD, DSc
Department of Vascular Diseases
University Medical Centre Ljubljana
Zaloska 7, 1525 Ljubljana, Slovenia
Phone: +386 1 522 80 32
Fax: +386 1 522 80 70
Email: ales.blinc@kclj.si
Publication History
Received:
07 June 2007
Accepted after major revision:
03 October 2007
Publication Date:
24 November 2017 (online)
-
References
- 1 D’Amato R, Loughnan M, Flynn E. et al. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994; 91: 4082-4085.
- 2 Teo SK. Properties of thalidomide and its analogues: implications for anticancer therapy. AAPS J 2005; 7: E14-19.
- 3 Brouillard P, Vikkula M. Vascular malformations: localized defects in vascular morphogenesis. Clin Genet 2003; 63: 340-351.
- 4 Lee BB. Advanced management of congenital vascular malformations (CVM). Int Angiol 2002; 21: 209-213.
- 5 Lee BB, Do YS, Yakes W. et al. Management of arteriovenous malformations: a multidisciplinary approach. J Vasc Surg 2004; 39: 590-600.
- 6 Lee BB. Critical issues in management of congenital vascular malformations. Ann Vasc Surg 2004; 18: 380-392.
- 7 Al-Shahi R, Warlow C. A systematic review of the frequency and prognosis of arteriovenous malformations of the brain in adults. Brain 2001; 124: 1900-1926.
- 8 Jeong HS, Baek CH, Son YI. et al. Treatment of extracranial arteriovenous malformations of the head and neck. Acta Otolaryngol 2006; 126: 295-300.
- 9 Plowman PN. Radiation therapy for vascular malformations – a changing scene. Clin Oncol 2002; 14: 91-96.
- 10 Andrade-Souza YM, Ramani M, Scora D. et al. Embolization before radiosurgery reduces the obliteration rate of arteriovenous malformations. Neurosurgery 2007; 60: 443-452.
- 11 Kilic K, Konya D, Kurtkaya O. et al. Inhibition of angiogenesis induced by cerebral arteriovenous malformations using gamma knife irradiation. J Neurosurg 2007; 106: 463-469.
- 12 Hanze J, Weissmann N, Grimminger F. et al. Cellular and molecular mechanisms of hypoxia-inducible factor driven vascular remodeling. Thromb Haemost 2007; 97: 774-787.
- 13 Hofer E, Schweighofer B. Signal transduction induced in endothelial cells by growth factor receptors involved in angiogenesis. Thromb Haemost 2007; 97: 355-363.
- 14 Mehrad B, Keane MP, Strieter RM. Chemokines as mediators of angiogenesis. Thromb Haemost 2007; 97: 755-762.
- 15 Frangogiannis NG. Chemokines in ischemia and reperfusion. Thromb Haemost 2007; 97: 738-747.
- 16 Belo AV, Leles F. Barcelos et al. Murine chemokine CXCL2/KC is a surrogate marker for angiogenic activity in the inflammatory granulation tissue. Microcirculation 2005; 12: 597-606.
- 17 Autiero M, Luttun A, Tjwa M. et al. Placental growth factor and its receptor, vascular endothelial growth factor receptor-1: novel targets for stimulation of ischemic tissue revascularization and inhibition of angiogenic and inflammatory disorders. J Thromb Haemost 2003; 1: 1356-1370.
- 18 Teo SK, Stirling DI, Zeldis JB. Thalidomide as a novel therapeutic agent: new uses for an old product. Drug Discov Today 2005; 10: 107-114.
- 19 Shurafa M, Kamboj G. Thalidomide for the treatment of bleeding angiodysplasias. Am J Gastroenterol 2003; 98: 221-222.
- 20 Kirkham SE, Lindley KJ, Elawad MA. et al. Treatment of multiple small bowel angiodysplasias causing severe life-threatening bleeding with thalidomide. J Pediatr Gastroenterol Nutr 2006; 42: 585-587.
- 21 Bauditz J, Lochs H, Voderholzer W. Macroscopic appearance of intestinal angiodysplasias under antiangiogenic treatment with thalidomide. Endoscopy 2006; 38: 1036-1039.
- 22 Heidt J, Langers AM, van der Meer FJ. et al. Thalidomide as treatment for digestive tract angiodysplasias. Neth J Med 2006; 64: 425-428.
- 23 Pérez-Encinas M, Rabuñal Martínez MJ, Bello López JL. Is thalidomide effective for the treatment of gastrointestinal bleeding in hereditary hemorrhagic telangiectasia?. Haematologica 2002; 87: ELT34.
- 24 Bauditz J, Schachschal G, Wedel S. et al. Thalidomide for treatment of severe intestinal bleeding. Gut 2004; 53: 609-612.
- 25 Hussein MA. Thromboembolism risk reduction in multiple myeloma patients treated with immunomodulatory drug combinations. Thromb Haemost 2006; 95: 924-930.
- 26 El Accaoui RN, Shamseddeen WA, Taher AT. Thalidomide and thrombosis. A meta-analysis. Thromb Haemost 2007; 97: 1031-1036.
- 27 Goz M, Eren MN, Cakir O. Arterial thrombosis and thalidomide. J Thromb Thrombolysis. 2007 epub ahead of print.
- 28 Altintas A, Ayyildiz O, Atay AE. et al. Thalidomideassociated arterial thrombosis: two case reports. Ann Acad Med Singapore 2007; 36: 304-306.
- 29 The Cleveland Clinic multiple Myeloma Research Center. Safety and tolerability of thalidomide. Available at: http://www.clevelandclinic.org/myeloma/safety_of_thalidomide.htm.
Correspondence to:
Ales Blinc, MD, DSc
Department of Vascular Diseases
University Medical Centre Ljubljana
Zaloska 7, 1525 Ljubljana, Slovenia
Phone: +386 1 522 80 32
Fax: +386 1 522 80 70
Email: ales.blinc@kclj.si
-
References
- 1 D’Amato R, Loughnan M, Flynn E. et al. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994; 91: 4082-4085.
- 2 Teo SK. Properties of thalidomide and its analogues: implications for anticancer therapy. AAPS J 2005; 7: E14-19.
- 3 Brouillard P, Vikkula M. Vascular malformations: localized defects in vascular morphogenesis. Clin Genet 2003; 63: 340-351.
- 4 Lee BB. Advanced management of congenital vascular malformations (CVM). Int Angiol 2002; 21: 209-213.
- 5 Lee BB, Do YS, Yakes W. et al. Management of arteriovenous malformations: a multidisciplinary approach. J Vasc Surg 2004; 39: 590-600.
- 6 Lee BB. Critical issues in management of congenital vascular malformations. Ann Vasc Surg 2004; 18: 380-392.
- 7 Al-Shahi R, Warlow C. A systematic review of the frequency and prognosis of arteriovenous malformations of the brain in adults. Brain 2001; 124: 1900-1926.
- 8 Jeong HS, Baek CH, Son YI. et al. Treatment of extracranial arteriovenous malformations of the head and neck. Acta Otolaryngol 2006; 126: 295-300.
- 9 Plowman PN. Radiation therapy for vascular malformations – a changing scene. Clin Oncol 2002; 14: 91-96.
- 10 Andrade-Souza YM, Ramani M, Scora D. et al. Embolization before radiosurgery reduces the obliteration rate of arteriovenous malformations. Neurosurgery 2007; 60: 443-452.
- 11 Kilic K, Konya D, Kurtkaya O. et al. Inhibition of angiogenesis induced by cerebral arteriovenous malformations using gamma knife irradiation. J Neurosurg 2007; 106: 463-469.
- 12 Hanze J, Weissmann N, Grimminger F. et al. Cellular and molecular mechanisms of hypoxia-inducible factor driven vascular remodeling. Thromb Haemost 2007; 97: 774-787.
- 13 Hofer E, Schweighofer B. Signal transduction induced in endothelial cells by growth factor receptors involved in angiogenesis. Thromb Haemost 2007; 97: 355-363.
- 14 Mehrad B, Keane MP, Strieter RM. Chemokines as mediators of angiogenesis. Thromb Haemost 2007; 97: 755-762.
- 15 Frangogiannis NG. Chemokines in ischemia and reperfusion. Thromb Haemost 2007; 97: 738-747.
- 16 Belo AV, Leles F. Barcelos et al. Murine chemokine CXCL2/KC is a surrogate marker for angiogenic activity in the inflammatory granulation tissue. Microcirculation 2005; 12: 597-606.
- 17 Autiero M, Luttun A, Tjwa M. et al. Placental growth factor and its receptor, vascular endothelial growth factor receptor-1: novel targets for stimulation of ischemic tissue revascularization and inhibition of angiogenic and inflammatory disorders. J Thromb Haemost 2003; 1: 1356-1370.
- 18 Teo SK, Stirling DI, Zeldis JB. Thalidomide as a novel therapeutic agent: new uses for an old product. Drug Discov Today 2005; 10: 107-114.
- 19 Shurafa M, Kamboj G. Thalidomide for the treatment of bleeding angiodysplasias. Am J Gastroenterol 2003; 98: 221-222.
- 20 Kirkham SE, Lindley KJ, Elawad MA. et al. Treatment of multiple small bowel angiodysplasias causing severe life-threatening bleeding with thalidomide. J Pediatr Gastroenterol Nutr 2006; 42: 585-587.
- 21 Bauditz J, Lochs H, Voderholzer W. Macroscopic appearance of intestinal angiodysplasias under antiangiogenic treatment with thalidomide. Endoscopy 2006; 38: 1036-1039.
- 22 Heidt J, Langers AM, van der Meer FJ. et al. Thalidomide as treatment for digestive tract angiodysplasias. Neth J Med 2006; 64: 425-428.
- 23 Pérez-Encinas M, Rabuñal Martínez MJ, Bello López JL. Is thalidomide effective for the treatment of gastrointestinal bleeding in hereditary hemorrhagic telangiectasia?. Haematologica 2002; 87: ELT34.
- 24 Bauditz J, Schachschal G, Wedel S. et al. Thalidomide for treatment of severe intestinal bleeding. Gut 2004; 53: 609-612.
- 25 Hussein MA. Thromboembolism risk reduction in multiple myeloma patients treated with immunomodulatory drug combinations. Thromb Haemost 2006; 95: 924-930.
- 26 El Accaoui RN, Shamseddeen WA, Taher AT. Thalidomide and thrombosis. A meta-analysis. Thromb Haemost 2007; 97: 1031-1036.
- 27 Goz M, Eren MN, Cakir O. Arterial thrombosis and thalidomide. J Thromb Thrombolysis. 2007 epub ahead of print.
- 28 Altintas A, Ayyildiz O, Atay AE. et al. Thalidomideassociated arterial thrombosis: two case reports. Ann Acad Med Singapore 2007; 36: 304-306.
- 29 The Cleveland Clinic multiple Myeloma Research Center. Safety and tolerability of thalidomide. Available at: http://www.clevelandclinic.org/myeloma/safety_of_thalidomide.htm.